Association betweenTCF7L2Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide

Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea

(2012) S. Seino   DIABETOLOGIA

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

(2011) Martin Javorsky et al.   European Journal of Internal Medicine

Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A

(2011) Veronica Y. Lang et al.   Pharmacogenetics and Genomics

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes

(2010) Z. Schroner et al.   DIABETES OBESITY & METABOLISM

Association between TCF7L2gene polymorphisms and susceptibility to Type 2 Diabetes Mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis

(2009) Yu Tong et al.   BMC Medical Genetics

TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action

(2009) D. T. Villareal et al.   DIABETES

The cAMP Sensor Epac2 Is a Direct Target of Antidiabetic Sulfonylurea Drugs

(2009) C.-L. Zhang et al.   SCIENCE

Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients

(2008) Y. Feng et al.   DIABETES CARE

Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation

(2008) Zhengyu Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE